|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: [email protected]. Type 508 Accommodation and the title of the report in the subject line of e-mail. Epidemiologic Notes and Reports Acute Hemorrhagic Conjunctivitis Caused by Coxsackievirus A24 -- CaribbeanIn the fall of 1986, large outbreaks of acute hemorrhagic conjunctivitis (AHC) occurred on the islands of Trinidad, Jamaica, and St. Croix. The outbreak on Trinidad was identified through a public health surveillance program for AHC initiated during the large outbreak of AHC caused by enterovirus 70 (EV70) in 1981. Beginning in October 1986, reported physician-diagnosed cases of AHC increased from 50-100 cases per 4-week period to 9,666 at the peak of the outbreak (Figure 3). By January of 1987, the number of reported cases had returned to background level. During the 3 outbreak months, a total of 15,396 cases of AHC were reported to the Ministry of Health. Two isolates were typed as coxsackievirus A24 variant (CA24v) by strain-specific neutralizing antisera. Between mid-October and late November, over 500 AHC patients who were self-referred and physician-diagnosed were seen at a hospital and ophthalmology clinic in Kingston, Jamaica. CA24v was isolated from five of the 15 AHC patients for whom viral cultures were performed. Three of four patients with acute- and convalescent-phase serum pairs available had a 16-fold rise in antibody titer (10 to 80) to the outbreak virus. Over 500 patients with AHC were also seen on the island of St. Croix in the Virgin Islands during October and November, but no isolates or serum specimens were obtained. Reported by: R Doug-Deen, MD, R Paul, MD, Ministry of Health, Welfare and Status of Women, Trinidad and Tobago; B Watson, PhD, Trinidad Public Health Laboratory; B Birju, SSO, National Surveillance Unit, Trinidad and Tobago. B Hull, PhD, Caribbean Epidemiology Centre; D King, MD, Univ of the West Indies, Kingston; H Vaughan, MD, Kingston Public Hospital; D Calder, MD, Kingston; P Figueroa, MD, Ministry of Health, Jamaica. A Anduze, MD, J Lewis, MD, St Croix Dept of Health, US Virgin Islands. Div of Viral Diseases, Center for Infectious Diseases, CDC. Editorial NoteEditorial Note: Both EV70 and CA24v have caused large outbreaks of AHC, usually in tropical, coastal cities; however, this is the first report of an isolation of CA24v in the western hemisphere. AHC, which follows an incubation period of 18 to 48 hours, is characterized by sudden onset of painful, swollen, red eyes with subconjunctival hemorrhaging, palpebral follicles, and excessive tearing (1). The symptoms usually persist for 3 to 5 days. The outbreaks have been explosive in nature, often affecting 50% or more of the persons in communities with a low socioeconomic status within a 1- to 2-month period (1). Spread appears to be related to crowding, poor hygiene, and other conditions characteristic of such communities (2). The first reports of AHC caused by EV70 were from western Africa in 1969; this virus has caused major pandemics since then (1). In 1981, during the last pandemic, EV70 was introduced into the western hemisphere and caused outbreaks in Central America, South America, and Florida (3-7). CA24v was first isolated during an outbreak in Singapore in 1970 (8). Prior to 1986, CA24v had not been reported outside of Southeast Asia and the Indian subcontinent (1). In 1986, CA24v was isolated during outbreaks in Taiwan, American Samoa, and India (CDC, unpublished data) (9). It is possible that CA24v, like EV70, may spread to other areas in the western hemisphere. EV70 and CA24v are antigenically unrelated, and infection with one virus does not induce neutralizing antibody against the other. This is particularly important in the diagnosis of AHC caused by EV70 because this virus is difficult to isolate. Attempts at viral culture of CA24v are more successful, with isolates often obtained from 40% of specimens using human cell lines (HeLa, HEp-2, HLF). EV70 outbreaks have also been diagnosed using an IgM capture enzyme-linked immunosorbent assay (ELISA) (10). Characterization of an isolate of either serotype usually is accomplished by neutralization studies with type-specific antisera, but it can also be accomplished by a monoclonal antibody ELISA as has been done with EV70 (11). Attempts to type CA24v isolates with polyclonal serum can sometimes be confused by a one-way cross reaction with echovirus 34 antisera. Echovirus 34 antiserum neutralizes CA24v, but CA24v antiserum does not neutralize echovirus 34 (12). Clinicians are encouraged to report cases of AHC caused by CA24v to their state or territorial health departments. They are also encouraged to send isolates of CA24v through their state or territorial laboratories to the Division of Viral Diseases, Center for Infectious Diseases, CDC. References
Disclaimer All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to [email protected].Page converted: 08/05/98 |
|||||||||
This page last reviewed 5/2/01
|